Provided is a head photic stimulation device including: a brain wave amplifier which subjects the subject brain waves acquired using a brain wave sensor to A/D conversion and amplification; a control signal generation circuit which, based on an output signal from the brain wave amplifier, generates a control signal for controlling LED driving; and a light irradiation unit which is driven based on an output from the control signal generation circuit, and which includes an LED for irradiating a head. The control signal generation circuit includes a band-pass filter for filtering an input signal, a DSP (signal processing) unit for controlling a signal that has passed through the band-pass filter, and a light irradiation output unit using a near-infrared LED for irradiating the head. The DSP unit has a feedback function for matching a phase of a PWM output for controlling the light irradiation output unit, in synchronism with the subject brain waves.

The present invention relates to a treatment apparatus and a control method for the treatment apparatus, and provides a treatment apparatus and a control method for the treatment apparatus, the treatment apparatus comprising: a treatment unit for transferring therapeutic energy at a preset period to a treatment position; a temperature measurement unit for measuring a temperature of the treatment position at a period different from the period at which the therapeutic energy is transferred; and a control unit for controlling an operation of the treatment unit on the basis of a result of measurement by the temperature measurement unit. The present invention enables a user to control a treatment content while accurately understanding the temperature of the treatment position, and thus can improve a treatment effect while preventing thermal damage to tissue.

An optical filter may reduce the frequency and/or severity of photophobic responses or for modulating circadian cycles by controlling light exposure to cells in the human eye in certain wavelengths, such as 480 nm and 590 nm, and a visual spectral response of the human eye. The optical filter may disrupt the isomerization of melanopsin in the human eye reducing the availability of the active isoform, whereas the attenuation of light weighted across the action potential spectrum of the active isoform attenuates the phototransduction cascade leading to photophobic responses. Embodiments of an optical filter are described. In one embodiment an optical filter may be configured to transmit less than a first amount of light in certain wavelengths, and to transmit more than a second amount of light weighted across the visual spectral response. Methods of use and methods of manufacturing optical filters are also described.

In various implementations, a device for stimulating the lacrimal gland and optionally the meibomian gland of an eye of a user by emitting light on the retina may include a control unit and an optical system connected to the control unit and arranged in the viewing direction of the user. The optical system may include at least one light source and may be configured for providing light stimulation pulses to an eye of the user by the at least one light source. Implementations of the device may also include a power supply unit for supplying power to the control unit and/or optical system. The light stimulation pulses activate the pupillary light reflex and one or more reflexes selected from blink reflex, corneal reflex, menace reflex, and lacrimal reflex. When the device is in operation mode a light intensity gradient between the light pulses emitted by the at least one light source and the light around the eye may be maintained at 2 or more lumens. The light stimulation pulses may induce blinking of the eye of the user.

A therapy, treatment and process for inactivating and/or killing COVID-19 (Corona Virus Disease 2019) is provided, including a low-dose, full body, Ultraviolet A1 (UV-A1, 360-400 nm) photon therapy, wherein the UV-A1 photon therapy activates singlet oxygen (.sup.1O.sub.2), which inactivates and/or kills COVID-19. UV-A1 therapy of the present invention can also be used to help alleviate symptoms and secondary illnesses caused by COVID-19. UV-A1 therapy of the present invention can also be used to help alleviate and treat pre-existing conditions of people that are also suffering from COVID-19 and worsened by COVID-19.

A computer implemented method for controlling a device adapted for projecting an image on at least a part of an eye of a wearer of said device, the method comprising the steps of providing the direction gaze of an eye of the wearer, providing an initial image to be projected, determining at least a filter depending from the provided gaze direction, filtering the initial image using the determined filter, and sending a command to the device for projecting the filtered image in the eye.

An ultraviolet light irradiation device includes an optical filter. The optical filter has a transmission spectrum of zero-degree light including a first transmission band and a second transmission band that transmit the zero-degree light and a first restriction band that restricts transmission of the zero-degree light. The first transmission band is present within the wavelength band of 200 nm or more and less than 240 nm. The second transmission band is present within a wavelength band of more than 300 nm and less than 400 nm. The first restriction band is present over an entire wavelength range of at least 240 nm or more and 300 nm or less, and the first restriction band has an upper limit provided within a range of more than 300 nm and 380 nm or less.

Provided is a light irradiation system and a light irradiation device that irradiate an eye of a subject with light having a predetermined wavelength band to produce a non-visual effect in mind and body of the subject. A light irradiation system according to an aspect of the present disclosure includes an irradiator configured to irradiate an eye of a subject with irradiation light having a predetermined wavelength band, and a shielding mechanism configured to decrease illuminance of light different from the irradiation light or decrease illuminance of light included in light different from the irradiation light and having a wavelength band different from the predetermined wavelength band.

Systems and methods of the present disclosure are directed to systems and methods for treating cognitive dysfunction in a subject in need thereof. The system can include eyeglasses, a photodiode positioned to detect ambient light, light sources, and an input device. The system can include a neural stimulation system that retrieves a profile and selects a light pattern having a fixed parameter and a variable parameter. The neural stimulation system can set a value of the variable parameter of the light pattern, construct an output signal, and then provide the output signal to the light sources to direct light towards the fovea.

There is provided a therapeutic method and system for utilizing full spectrum of natural solar radiations with an optimum balance of ultra-violet (UV), visible and infrared (IR) radiations. The disclosed therapeutic method comprising collecting and concentrating the natural solar radiations using a natural solar radiations concentrator; transporting the concentrated natural solar radiations using a transporting medium to an indoor device; optimizing a spot size, an intensity and an ultra-violet range of the natural solar radiations; and directing the optimized natural solar radiations to a desired body part using the indoor device; wherein the full spectrum of natural solar radiations has an optimum balance of ultra-violet, visible and infrared radiations. The disclosed therapeutic system comprising an outdoor device for collecting and concentrating the natural solar radiations; and an indoor device in optical communication with the outdoor device for adjusting and directing an optimized amount of the natural solar radiations to a desired body part.